Topical and intralesional treatment of nonmelanoma skin cancer: Efficacy and cost comparisons

Dermatologic Surgery

Volumn 39, Issue 9, 2013, Pages 1306-1316

  Chitwood, Katelyn ^a   Etzkorn, Jeremy ^b   Cohen, George ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BETA INTERFERON; BLEOMYCIN; FLUOROURACIL; GAMMA INTERFERON; IMIQUIMOD; METHOTREXATE; THYMIDYLATE SYNTHASE;

COST EFFECTIVENESS ANALYSIS; DNA SYNTHESIS; DRUG CLEARANCE; DRUG EFFICACY; FOLLOW UP; HEALTH CARE COST; HUMAN; KERATOACANTHOMA; NON MELANOMA SKIN CANCER; OFF LABEL DRUG USE; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BLEOMYCIN; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; FLUOROURACIL; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON-ALPHA; KERATOACANTHOMA; METHOTREXATE; RECOMBINANT PROTEINS; SKIN NEOPLASMS;

EID: 84883557025     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/dsu.12300     Document Type: Review

References (71)

1. Kirby JS, Miller CJ,. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol 2010; 63: 689-702.
2. Choudhary S, Tang J, Elsaie ML, Nouri K,. Lasers in the treatment of nonmelanoma skin cancer. Dermatol Surg 2011; 37: 409-25.
3. Gaspari AA, Sauder DN,. Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg 2003; 29: 1027-34.
4. Wolverton SE,. Comprehensive dermatologic drug therapy. Philadelphia: Saunders; 2001.
5. Marks R, Gebauer K, Shumack S, Amies M, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-13.
6. Cowen E, Mercurio MG, Gaspari AA,. An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream. J Am Acad Dermatol 2002; 47: S240-8.
7. Geisse JK, Rich P, Pandya A, Gross K, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-8.
8. Sterry W, Ruzicka T, Herrera E, Takwale A, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227-36.
9. Bianchi L, Costanzo A, Campione E, Nistico S, et al. Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients. Clin Exp Dermatol 2003; 28 (Suppl 1): 24-6.
10. Geisse J, Caro I, Lindholm J, Golitz L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-33.
11. Marks R, Owens M, Walters SA,. Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas. Arch Dermatol 2004; 140: 1284-5.
12. Shumack S, Gebauer K, Quirk C, Macdonald K, et al. 5% imiquimod cream for the treatment of large superficial basal cell carcinoma. Arch Dermatol 2004; 140: 1286-7.
13. Peris K, Campione E, Micantonio T, Marulli GC, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005; 31: 318-23.
14. Schulze HJ, Cribier B, Requena L, Reifenberger J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152: 939-47.
15. Vun Y, Siller G,. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J Dermatol 2006; 47: 169-71.
16. Schiessl C, Wolber C, Tauber M, Offner F, et al. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol 2007; 6: 507-13.
17. Vidal D, Matias-Guiu X, Alomar A,. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol 2007; 143: 266-8.
18. Gollnick H, Barona CG, Frank RG, Ruzicka T, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 2008; 18: 677-82.
19. Quirk C, Gebauer K, De'Ambrosis B, Slade HB, et al. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis 2010; 85: 318-24.
20. Valeant Pharmaceuticals International. Efudex-40™ (fluorouracil topical cream) prescribing information. Costa Mesa (CA): Valeant Pharmaceuticals International; 2004.
21. Gross K, Kircik L,. 5% 5-fluorouracil cream for the treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg 2007; 33: 433-9; discussion 40.
22. Shumack S, Robinson J, Kossard S, Golitz L, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002; 138: 1165-71.
23. Huber A, Huber JD, Skinner RB Jr, Kuwahara RT, et al. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol Surg 2004; 30: 429-30.
24. Eigentler TK, Kamin A, Weide BM, Breuninger H, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol 2007; 57: 616-21.
25. Leppala J, Kaarniranta K, Uusitalo H, Kontkanen M,. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand 2007; 85: 566-8.
26. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44: 462-70.
27. Prinz BM, Hafner J, Dummer R, Burg G, et al. Treatment of Bowen's disease with imiquimod 5% cream in transplant recipients. Transplantation 2004; 77: 790-1.
28. Mandekou-Lefaki I, Delli F, Koussidou-Eremondi T, Mourellou-Tsatsou O, et al. Imiquimod 5% cream: a new treatment for Bowen's disease. Int J Tissue React 2005; 27: 31-8.
29. Patel GK, Goodwin R, Chawla M, Laidler P, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006; 54: 1025-32.
30. Peris K, Micantonio T, Fargnoli MC, Lozzi GP, et al. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J Am Acad Dermatol 2006; 55: 324-7.
31. Rosen T, Harting M, Gibson M,. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg 2007; 33: 427-31; discussion 31-2.
32. Jeon HC, Choi M, Paik SH, Ahn CH, et al. Treatment of keratoacanthoma with 5% imiquimod cream and review of the previous report. Ann Dermatol 2011; 23: 357-61.
33. Bargman H, Hochman J,. Topical treatment of Bowen's disease with 5-Fluorouracil. J Cutan Med Surg 2003; 7: 101-5.
34. Salim A, Leman JA, McColl JH, Chapman R, et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 2003; 148: 539-43.
35. Morton C, Horn M, Leman J, Tack B, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 2006; 142: 729-35.
36. Avant WH, Huff RC,. Intradermal 5-fluorouracil in the treatment of basal cell carcinoma of the face. South Med J 1976; 69: 561-3.
37. Kurtis B, Rosen T,. Treatment of cutaneous neoplasms by intralesional injections of 5-fluorouracil (5-FU). J Dermatol Surg Oncol 1980; 6: 122-7.
38. Klein E, Helm F, Milgrom H, Stoll HL Jr, et al. Tumors of the skin. II. Keratoacanthoma; local effct of 5-fluorouracil. Skin (Los Angeles) 1962; 1: 153-6.
39. Goette DK, Odom RB,. Successful treatment of keratoacanthoma with intralesional fluorouracil. J Am Acad Dermatol 1980; 2: 212-6.
40. Parker CM, Hanke CW,. Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil. J Am Acad Dermatol 1986; 14: 770-7.
41. Melton JL, Nelson BR, Stough DB, Brown MD, et al. Treatment of keratoacanthomas with intralesional methotrexate. J Am Acad Dermatol 1991; 25: 1017-23.
42. Cuesta-Romero C, de Grado-Pena J,. Intralesional methotrexate in solitary keratoacanthoma. Arch Dermatol 1998; 134: 513-4.
43. Annest NM, VanBeek MJ, Arpey CJ, Whitaker DC,. Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature. J Am Acad Dermatol 2007; 56: 989-93.
44. Mishima Y, Matunaka M,. Effect of bleomycin on benign and malignant cutaneous tumours. Acta Derm Venereol 1972; 52: 211-5.
45. Sayama S, Tagami H,. Treatment of keratoacanthoma with intralesional bleomycin. Br J Dermatol 1983; 109: 449-52.
46. Greenway HT, Cornell RC, Tanner DJ, Peets E, et al. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 1986; 15: 437-43.
47. Wickramasinghe L, Hindson TC, Wacks H,. Treatment of neoplastic skin lesions with intralesional interferon. J Am Acad Dermatol 1989; 20: 71-4.
48. Grob JJ, Collet AM, Munoz MH, Bonerandi JJ,. Treatment of large basal-cell carcinomas with intralesional interferon-alpha-2a. Lancet 1988; 1: 878-9.
49. Dogan B, Harmanyeri Y, Baloglu H, Oztek I,. Intralesional alfa-2a interferon therapy for basal cell carcinoma. Cancer Lett 1995; 91: 215-9.
50. LeGrice P, Baird E, Hodge L,. Treatment of basal cell carcinoma with intralesional interferon alpha-2a. N Z Med J 1995; 108: 206-7.
51. Alpsoy E, Yilmaz E, Basaran E, Yazar S,. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. J Dermatol 1996; 23: 394-6.
52. Bostanci S, Kocyigit P, Alp A, Erdem C, et al. Treatment of Basal Cell Carcinoma Located in the Head and Neck Region with Intralesional Interferon alpha-2a: evaluation of Long-Term Follow-Up Results. Clin Drug Investig 2005; 25: 661-7.
53. Grob JJ, Suzini F, Richard MA, Weiller M, et al. Large keratoacanthomas treated with intralesional interferon alfa-2a. J Am Acad Dermatol 1993; 29: 237-41.
54. Cornell RC, Greenway HT, Tucker SB, Edwards L, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990; 23: 694-700.
55. Edwards L, Tucker SB, Perednia D, Smiles KA, et al. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas. Arch Dermatol 1990; 126: 1029-32.
56. Mozzanica N, Cattaneo A, Boneschi V, Brambilla L, et al. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon. Arch Dermatol Res 1990; 282: 311-7.
57. Thestrup-Pedersen K, Jacobsen IE, Frentz G,. Intralesional interferon-alpha 2b treatment of basal cell carcinoma. Acta Derm Venereol 1990; 70: 512-4.
58. Boneschi V, Brambilla L, Chiappino G, Mozzanica N, et al. Intralesional alpha 2b recombinant interferon for basal cell carcinomas. Int J Dermatol 1991; 30: 220-4.
59. Healsmith MF, Berth-Jones J, Fletcher A, Graham-Brown RA,. Treatment of basal cell carcinoma with intralesional interferon alpha-2b. J R Soc Med 1991; 84: 524-6.
60. Pizarro A, Fonseca E,. Treatment of basal cell carcinoma with intralesional interferon alpha-2b: evaluation of efficacy with emphasis on tumors located on 'H' zone of the face. Eur J Dermatol 1994; 4: 287-90.
61. Chimenti S, Peris K, Di Cristofaro S, Fargnoli MC, et al. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology 1995; 190: 214-7.
62. Tucker SB, Polasek JW, Perri AJ, Goldsmith EA,. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol 2006; 54: 1033-8.
63. Stenquist B, Wennberg AM, Gisslen H, Larko O,. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery. J Am Acad Dermatol 1992; 27: 65-9.
64. Kim KH, Yavel RM, Gross VL, Brody N,. Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited. Dermatol Surg 2004; 30: 116-20.
65. Oh CK, Son HS, Lee JB, Jang HS, et al. Intralesional interferon alfa-2b treatment of keratoacanthomas. J Am Acad Dermatol 2004; 51: S177-80.
66. Edwards L, Berman B, Rapini RP, Whiting DA, et al. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Arch Dermatol 1992; 128: 1486-9.
67. Kowalzick L, Rogozinski T, Schober C, Fierlbeck G, et al. Treatment of basal cell carcinoma with intralesional recombinant interferon beta: a dose-finding study. Eur J Dermatol 1994; 4: 430-3.
68. Kowalzick L, Rogozinski T, Wimheuer R, Pilz J, et al. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study. Eur J Dermatol 2002; 12: 558-61.
69. Edwards L, Whiting D, Rogers D, Luck K, et al. The effect of intralesional interferon gamma on basal cell carcinomas. J Am Acad Dermatol 1990; 22: 496-500.
70. Tank B, Habets JM, Naafs B, Damsma O, et al. Intralesional treatment of basal cell carcinoma with low-dose recombinant interferon gamma. J Am Acad Dermatol 1989; 21: 734-5.
71. Cribier B, Asch P, Grosshans E,. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology 1999; 199: 208-12